Anti-Parkinson Drugs Global Market Report 2025

Description

Anti-Parkinson drugs are medications primarily utilized for the treatment of Parkinson's disease. It's important to note that these drugs are not psychiatric medications and are not intended for the treatment of mental health issues. However, in some cases, a doctor or psychiatrist may recommend the use of these medications in addition to antipsychotics to mitigate certain negative effects associated with the latter.

The main categories of anti-Parkinson drugs include levodopa/carbidopa, dopamine receptor agonists, monoamine oxidase type B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, anticholinergics, and other drugs. Catechol-O-methyltransferase (COMT) inhibitors represent a specific class of drugs used in conjunction with carbidopa-levodopa therapy to manage Parkinson's disease symptoms effectively. These medications can be administered through various routes, including oral, injection, and transdermal methods, and they are typically dispensed through hospital pharmacies, retail pharmacies, and online pharmacies.

The anti-Parkinson drugs market research report is one of a series of new reports from The Business Research Company that provides anti-Parkinson drugs market statistics, including anti-Parkinson drugs industry global market size, regional shares, competitors with an anti-Parkinson drugs market share, detailed anti-Parkinson drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-Parkinson drugs industry. This anti-Parkinson drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The anti-parkinson drugs market size has grown strongly in recent years. It will grow from $10.37 billion in 2024 to $11.08 billion in 2025 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to aging population, increasing disease prevalence, healthcare infrastructure, advancements in research.

The anti-parkinson drugs market size is expected to see strong growth in the next few years. It will grow to $13.73 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to growing awareness, biotechnological advancements, emerging markets. Major trends in the forecast period include investment in r&d, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine and remote monitoring, biosimilars, research collaborations.

The anticipated growth in the demand for anti-Parkinson drugs is driven by the increasing geriatric population and the rising number of cases of Parkinson's disease (PD). PD is commonly diagnosed in individuals over the age of 60, making it a particular concern for the elderly population. For example, data from the World Health Organization indicates that globally, the proportion of individuals aged 60 or older is expected to reach 1 in 6 by 2030, and this figure is projected to double by 2050, reaching 2.1 billion individuals in this age group. Similarly, data from the UK Parliament's House of Commons Library reveals that the elderly population in the UK is expected to grow significantly, accounting for 24% of the total population (17.4 million people) by 2043. This demographic shift towards an older population is a key driver of the increasing demand for anti-Parkinson drugs, given the higher prevalence of PD in the elderly.

The expected growth in the anti-Parkinson drugs market is being propelled by the increasing incidence of mental health disorders. Mental health disorders represent a clinically significant impairment in an individual's cognitive, emotional regulation, or behavior, often associated with distress and functional impairment in various areas of life. The rise in mental health disorders has a direct impact on the anti-Parkinson drugs market, as these drugs play a crucial role in mitigating and treating these disorders. For example, data from the Health and Social Care Information Centre in the UK reveals a notable increase in the proportion of 17- to 19-year-olds with suspected mental disorders, rising from 17.4% in 2021 to 25.7% in 2022. This data illustrates the growing prevalence of mental health disorders, which, in turn, drives the demand for anti-Parkinson drugs. The connection between these two factors underscores the importance of anti-Parkinson drugs in addressing the mental health needs of individuals affected by Parkinson's disease and related conditions.

The anticipated growth of the anti-Parkinson's drug market may face limitations due to the high cost associated with the treatment of Parkinson's disease. According to statistics from the Michael J. Fox Foundation for Parkinson's Research, the economic burden of Parkinson's disease is on the rise and affects patients, their families, and the federal government. In the United States, the overall cost of Parkinson's disease amounts to $51.9 billion annually, with $25.4 billion allocated to direct medical costs, including expenses related to hospitalization and medication. This significant financial burden on individuals, families, and healthcare systems underscores the high cost of managing Parkinson's disease. Consequently, the expense of treating the condition can potentially restrict access to anti-Parkinson drugs and influence the market's growth dynamics. Finding cost-effective solutions and approaches to Parkinson's disease treatment will be a key consideration for stakeholders in the anti-Parkinson's drug market.

Major companies in the anti-Parkinson drugs market are increasingly focused on developing advanced therapeutic solutions to address challenges such as motor fluctuations and dyskinesia, which complicate Parkinson's disease treatment and impact patient well-being. For example, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA, the first subcutaneous 24-hour infusion therapy for advanced Parkinson's disease. PRODUODOPA (foslevodopa/foscarbidopa) specifically targets severe motor fluctuations and dyskinesia in patients for whom other treatments have failed. The therapy continuously delivers levodopa, potentially increasing "on" time and improving symptom control.

A significant trend in the anti-Parkinson drugs market is the increased investment from both government and corporate sources in research and development for drugs related to Parkinson's disease. For example, in August 2022, the Parkinson's Foundation, a prominent national organization in the United States, announced a substantial investment of $5.7 million into 33 research projects. This funding is aimed at accelerating cutting-edge research in the field of Parkinson's disease. By providing research grants, the foundation supports scientists in conducting innovative studies on various aspects of Parkinson's disease. The ultimate goal is to develop new therapies, treatments, and, ideally, a cure for the approximately 10 million individuals worldwide who are affected by this debilitating neurological condition. As a result, the increased investments in Parkinson's drug development are expected to be a driving force in the anti-Parkinson drugs market.

In October 2023, AbbVie Inc., a US-based pharmaceutical company, acquired Mitokinin for $110 million. This acquisition is part of AbbVie's strategy to strengthen its neuroscience pipeline and expand treatment options for Parkinson's disease (PD) patients. Mitokinin, a US-based biotechnology company, specializes in developing treatments for Parkinson's disease.

Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

North America was the largest region in the anti-Parkinson drugs market in 2024. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the anti-parkinson drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The anti-parkinson drugs market consists of sales of catechol-O-methyl transferase [COMT] inhibitors, anticholinergic drugs, and amantadine. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Anti-Parkinson Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on anti-parkinson drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for anti-parkinson drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-parkinson drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Drugs Class: Levodopa Or Carbidopa; Dopamine Receptor Agonists; Monoamine Oxidase Type B (MAO-B) Inhibitors; Catechol-O-Methyltransferase (COMT)-inhibitors; Anticholinergics; Other Drugs
2) By Route of Administration: Oral; Injection; Transdermal
3) By Distribution Channel: Hospital Pharmacies; Retailer Pharmacies; Online Pharmacies
Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa; Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole; Ropinirole; Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline; Rasagiline; Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone; Tolcapone
5) By Anticholinergics: Benztropine; Trihexyphenidyl
6) By Other Drugs: Amantadine; Apomorphine
Companies Mentioned: GlaxoSmithKline plc; Pfizer Inc.; Merck Co.; Novartis AG; F. Hoffmann-La Roche AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r32387

1. Executive Summary

2. Anti-Parkinson Drugs Market Characteristics

3. Anti-Parkinson Drugs Market Trends And Strategies

4. Anti-Parkinson Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Anti-Parkinson Drugs Growth Analysis And Strategic Analysis Framework

5.1. Global Anti-Parkinson Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Anti-Parkinson Drugs Market Growth Rate Analysis
5.4. Global Anti-Parkinson Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Anti-Parkinson Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Anti-Parkinson Drugs Total Addressable Market (TAM)

6. Anti-Parkinson Drugs Market Segmentation

6.1. Global Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Levodopa Or Carbidopa
Dopamine Receptor Agonists
Monoamine Oxidase Type B (MAO-B) Inhibitors
Catechol-O-Methyltransferase (COMT)-inhibitors
Anticholinergics
Other Drugs
6.2. Global Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Injection
Transdermal
6.3. Global Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retailer Pharmacies
Online Pharmacies
6.4. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Levodopa Or Carbidopa, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immediate-Release Levodopa Or Carbidopa
Extended-Release Levodopa Or Carbidopa
6.5. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Dopamine Receptor Agonists, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pramipexole
Ropinirole
Rotigotine
6.6. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Monoamine Oxidase Type B (MAO-B) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Selegiline
Rasagiline
Safinamide
6.7. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Catechol-O-Methyltransferase (COMT)-Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Entacapone
Tolcapone
6.8. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Anticholinergics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Benztropine
Trihexyphenidyl
6.9. Global Anti-Parkinson Drugs Market, Sub-Segmentation Of Other Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Amantadine
Apomorphine

7. Anti-Parkinson Drugs Market Regional And Country Analysis

7.1. Global Anti-Parkinson Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Anti-Parkinson Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Anti-Parkinson Drugs Market

8.1. Asia-Pacific Anti-Parkinson Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Anti-Parkinson Drugs Market

9.1. China Anti-Parkinson Drugs Market Overview
9.2. China Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Anti-Parkinson Drugs Market

10.1. India Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Anti-Parkinson Drugs Market

11.1. Japan Anti-Parkinson Drugs Market Overview
11.2. Japan Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Anti-Parkinson Drugs Market

12.1. Australia Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Anti-Parkinson Drugs Market

13.1. Indonesia Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Anti-Parkinson Drugs Market

14.1. South Korea Anti-Parkinson Drugs Market Overview
14.2. South Korea Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Anti-Parkinson Drugs Market

15.1. Western Europe Anti-Parkinson Drugs Market Overview
15.2. Western Europe Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Anti-Parkinson Drugs Market

16.1. UK Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Anti-Parkinson Drugs Market

17.1. Germany Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Anti-Parkinson Drugs Market

18.1. France Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Anti-Parkinson Drugs Market

19.1. Italy Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Anti-Parkinson Drugs Market

20.1. Spain Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Anti-Parkinson Drugs Market

21.1. Eastern Europe Anti-Parkinson Drugs Market Overview
21.2. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Anti-Parkinson Drugs Market

22.1. Russia Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Anti-Parkinson Drugs Market

23.1. North America Anti-Parkinson Drugs Market Overview
23.2. North America Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Anti-Parkinson Drugs Market

24.1. USA Anti-Parkinson Drugs Market Overview
24.2. USA Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Anti-Parkinson Drugs Market

25.1. Canada Anti-Parkinson Drugs Market Overview
25.2. Canada Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Anti-Parkinson Drugs Market

26.1. South America Anti-Parkinson Drugs Market Overview
26.2. South America Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Anti-Parkinson Drugs Market

27.1. Brazil Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Anti-Parkinson Drugs Market

28.1. Middle East Anti-Parkinson Drugs Market Overview
28.2. Middle East Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Anti-Parkinson Drugs Market

29.1. Africa Anti-Parkinson Drugs Market Overview
29.2. Africa Anti-Parkinson Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Anti-Parkinson Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Anti-Parkinson Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Anti-Parkinson Drugs Market Competitive Landscape And Company Profiles

30.1. Anti-Parkinson Drugs Market Competitive Landscape
30.2. Anti-Parkinson Drugs Market Company Profiles
- 30.2.1. GlaxoSmithKline plc Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck Co. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. F. Hoffmann-La Roche AG Overview, Products and Services, Strategy and Financial Analysis

31. Anti-Parkinson Drugs Market Other Major And Innovative Companies

31.1. UCB S.A
31.2. Teva Pharmaceutical Industries Ltd.
31.3. AbbVie Inc.
31.4. Mylan NV
31.5. C.H. Boehringer Sohn AG & Co. KG
31.6. Orion Pharma Ltd.
31.7. ACADIA Pharmaceuticals Inc.
31.8. Sun Pharmaceutical Industries Ltd.
31.9. Wockhardt Ltd.
31.10. Reddy's Laboratories Ltd.
31.11. Intas Pharmaceuticals Ltd.
31.12. US WorldMeds LLC
31.13. Zydus Lifesciences Limited
31.14. Chemical Industrial & Pharmaceutical Laboratories Ltd.
31.15. Strides Shasun Ltd.

32. Global Anti-Parkinson Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Market

34. Recent Developments In The Anti-Parkinson Drugs Market

35. Anti-Parkinson Drugs Market High Potential Countries, Segments and Strategies

35.1 Anti-Parkinson Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Anti-Parkinson Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Anti-Parkinson Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer